Drug Trial Radar · NCT05356741
To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
645
Planned (sponsor's estimate)
Start
Apr 13, 2022
Primary completion
Apr 2028
Study completion Apr 2028
Sponsor
- Lead sponsor
- Vir Biotechnology, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- May 2, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This first-in-human (FIH) Phase 1 open-label multicenter dose-escalation and dose-expansion study is designed to evaluate the safety, pharmacokinetics, and preliminary activity of VIR-5818 (Formerly AMX-818) as a single agent and in combination with pembrolizumab in participants with HER2+ tumors across multiple tumor types. The study will be conducted in four parts: * Part 1 (dose escalation): Single-agent VIR-5818 * Part 2 (dose escalation): VIR-5818 plus pembrolizumab * Part 3 (dose expansion): Single-agent VIR-5818 * Part 4 (dose expansion): VIR-5818 plus pembrolizumab The total length of the study, from screening of the first participant to the end of the study, is expected to be approximately 72 months.
Conditions
- Locally Advanced or Metastatic HER2-Expressing Cancers
Interventions
VIR-5818Drug
Administered as IV infusion
pembrolizumabDrug
Administered as IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose-limiting toxicity - Part 1 and Part 2Time frame: Up to approximately 21 days (Part 1) and 42 days (Part 2)
- Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)- Parts 1, 2, 3, and 4Time frame: Up to approximately 55 months
- Objective Response Rate (ORR) - Part 3 and Part 4Time frame: Up to approximately 55 months
- Duration of Response (DOR) - Part 3 and Part 4Time frame: Up to approximately 55 months
Locations
13 sites in 5 countries. Site status is shown where the registry gives one.
Investigational site number #450
Duarte, California · Recruiting
Investigational site number #451
Palo Alto, California · Recruiting
Investigational site number #101
Randwick, Australia · Recruiting
Investigational site number #100
Melbourne, Victoria, Australia · Active not recruiting
Investigational site number #150
Toulouse, France · Recruiting
Investigational site number #200
Porto, Portugal · Recruiting
Investigational site number #255
Barcelona, Spain · Recruiting
Investigational site number #251
Barcelona, Spain · Recruiting
Investigational site number #254
Madrid, Spain · Recruiting
Investigational site number #257
Madrid, Spain · Recruiting
Investigational site number #252
Madrid, Spain · Recruiting
Investigational site number #250
Pamplona, Spain · Recruiting
Investigational site number #253
Pozuelo de Alarcón, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.